We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
In this commentary, the authors highlight the collateral risk to patients with COPD in the current COVID-19 pandemic. They discuss situations like delayed or incomplete treatment of acute exacerbation of COPD and decreased access to medications.
The authors have highlighted an important clinical situation, and they also provide strategies to mitigate these risks, which may be clinically useful.
– Morgan Soffler, MD
This abstract is available on the publisher's site.
The unprecedented coronavirus disease (COVID) pandemic is rapidly taking its toll on the world population, health-care systems and workers, and global resources. Treatment accommodations and choices within the health-care system to address COVID are likely to have unintended consequences for patients with existing chronic diseases. Patients with COPD, for instance, are a high-risk population at risk for “collateral damage” during the COVID-19 pandemic. We summarize the current evidence base for potential harm or risk of harm to patients with COPD during the COVID-19 pandemic and propose some strategies to mitigate those risks.